What this pack is
ZOVIRAX is the brand name in this record; acyclovir oral capsules tablets and suspension is the generic name. Read both together with the dosage form (multiple oral forms (tablets and oral liquid)).
PACK CHECK · MARKET FIRST
ZOVIRAXGeneric nameacyclovir oral capsules tablets and suspension
How this medicine works
The historical FDA label describes acyclovir as a synthetic nucleoside analogue active against herpesviruses. The mechanism explains why form, exact diagnosis, kidney function and the complete medicine list matter; it cannot decide from a rash, pain, blisters or another person's experience whether someone needs it, how to use it or for how long.
Read source: United States ↗reviewed 2026-09-13More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- ZOVIRAX
- Generic name
- acyclovir oral capsules tablets and suspension
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PACKAGE-VISUAL STATUS
ZOVIRAX image withheld: a historical brand file and current generic labels are not one package
This page retains historical ZOVIRAX oral-product identity and current public generic acyclovir labels, but no public primary image is retained that matches current ZOVIRAX, one exact form, one exact strength and one exact pack one-to-one. To avoid presenting generic, topical, injectable, other-market or historical imagery as the visitor's product, no pack or tablet visual is displayed.
LABEL READING · NOT A PRESCRIPTION
ZOVIRAX / acyclovir label reading: first separate per tablet, per capsule and per 5 mL
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The historical ZOVIRAX label lists capsules, tablets and suspension separately, and current public reading sources are also separate capsule/tablet and suspension labels. This module helps check the exact form, label unit and urgent-risk cues; it provides no individual tablet, capsule, millilitre, frequency or course instruction.
- A 200 mg capsule is an amount per capsule; 400 mg and 800 mg are amounts per tablet; 200 mg/5 mL is an amount in each 5 mL of liquid. They are not numbers to add, convert by experience or turn into an individual's capsule, tablet or millilitre answer.
- Capsules, tablets and suspension cannot be self-substituted from a shared acyclovir name or total milligrams. A liquid also requires checking its concentration, measuring device, label and actual prescription together. Swallowing difficulty, an unclear device or a different pack needs pharmacist review first.
- Current generic labels include kidney-related risk and rare serious skin-reaction cues. Marked urine change, unusual drowsiness or altered awareness, extensive rash, mouth/eye mucosal involvement, breathing difficulty or another acute serious concern needs timely local medical support. Do not self-increase, stop or share leftover medicine.
- This oral ZOVIRAX archive excludes topical ointment, cream and injection; VALTREX / valacyclovir is also a different medicine. A related antiviral use does not permit self-rotation, co-use or milligram conversion.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkFDA · United States · Regulatory product record or label archive · 2026-09-13
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 4
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeFDA: ZOVIRAX (acyclovir) 2008 U.S. oral capsule, tablet and suspension prescribing information; the document expressly states it may not be the latest approved label ↗reviewed 2026-09-13
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-29FDA Orange Book data files: lookup entry for historical U.S. ZOVIRAX oral-capsule NDA 018828, oral-suspension NDA 019909 and oral-tablet NDA 020089 records ↗reviewed 2026-08-29
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-13DailyMed (NLM): current U.S. generic acyclovir 200 mg capsule and tablet label (EMC Pharma; updated Dec 2024) ↗reviewed 2026-09-13
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-13DailyMed (NLM): current U.S. generic acyclovir oral-suspension label (updated Jan 2025) ↗reviewed 2026-09-13
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about ZOVIRAX (acyclovir oral capsules tablets and suspension). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
ZOVIRAX is the brand in this record and acyclovir oral capsules tablets and suspension is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- FDA: ZOVIRAX (acyclovir) 2008 U.S. oral capsule, tablet and suspension prescribing information; the document expressly states it may not be the latest approved label ↗reviewed 2026-09-13
- FDA Orange Book data files: lookup entry for historical U.S. ZOVIRAX oral-capsule NDA 018828, oral-suspension NDA 019909 and oral-tablet NDA 020089 records ↗reviewed 2026-08-29
- DailyMed (NLM): current U.S. generic acyclovir 200 mg capsule and tablet label (EMC Pharma; updated Dec 2024) ↗reviewed 2026-09-13
- DailyMed (NLM): current U.S. generic acyclovir oral-suspension label (updated Jan 2025) ↗reviewed 2026-09-13
HOW IT WORKS · NOT A TREATMENT PLAN
How acyclovir works: a viral-DNA-polymerase mechanism does not mean every rash needs medicine
- “Antiviral” is not a universal conclusion for every infection, mouth sore, rash or cold. Do not start, extend, combine or share acyclovir from similar symptoms, travel history or leftover household medicine.
- If valacyclovir, another antiviral, immunosuppression, pain medicines or medicines that may affect kidneys appear on the list, review the exact products, kidney information and complete list item by item. The site does not set separation times or adjust a dose.
- Even a similar symptom name, virus name or another person's prescription cannot replace diagnosis, testing or follow-up. The responsible team uses the exact indication, age, immune status, kidney function, pregnancy-related information and local label to decide next steps; the site does not replace that judgment.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: ZOVIRAX (acyclovir) 2008 U.S. oral capsule, tablet and suspension prescribing information; the document expressly states it may not be the latest approved label ↗reviewed 2026-09-13
- FDA Orange Book data files: lookup entry for historical U.S. ZOVIRAX oral-capsule NDA 018828, oral-suspension NDA 019909 and oral-tablet NDA 020089 records ↗reviewed 2026-08-29
- DailyMed (NLM): current U.S. generic acyclovir 200 mg capsule and tablet label (EMC Pharma; updated Dec 2024) ↗reviewed 2026-09-13
- DailyMed (NLM): current U.S. generic acyclovir oral-suspension label (updated Jan 2025) ↗reviewed 2026-09-13
SOURCE-TRACEABLE ARCHIVE
ZOVIRAXacyclovir oral capsules tablets and suspension
This page links to public primary-source material for ZOVIRAX. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Historical FDA application node for ZOVIRAX 200 mg oral capsules
FDA regulatory material links NDA 018828 with ZOVIRAX 200 mg oral capsules. The date locates a historical U.S. record, not current supply, anyone's start date or prescription frequency.
FDA Orange Book data files: lookup entry for historical U.S. ZOVIRAX oral-capsule NDA 018828, oral-suspension NDA 019909 and oral-tablet NDA 020089 records ↗Historical FDA application node for ZOVIRAX 200 mg/5 mL oral suspension
FDA regulatory material links NDA 019909 with oral suspension; its liquid concentration cannot be directly exchanged with capsule or tablet numbers.
FDA Orange Book data files: lookup entry for historical U.S. ZOVIRAX oral-capsule NDA 018828, oral-suspension NDA 019909 and oral-tablet NDA 020089 records ↗Historical FDA application node for ZOVIRAX 400 mg/800 mg oral tablets
FDA regulatory material links NDA 020089 separately with 400 mg and 800 mg oral tablets. Both strengths are product-identity fields, not an individual-use or conversion instruction.
FDA Orange Book data files: lookup entry for historical U.S. ZOVIRAX oral-capsule NDA 018828, oral-suspension NDA 019909 and oral-tablet NDA 020089 records ↗
MARKET SCOPE
Market-record boundary
United States
Historical ZOVIRAX oral file and current generic reading entries linked separatelyThe historical brand file and current generic labels are retained separately, avoiding any statement that a historical brand document is a current label or stock record.
Mainland China, Japan, EU and other markets
Current market record not establishedNo local trade name, approval, pack, supply, originator relationship or interchangeability is inferred from the U.S. historical brand, generic labels or a shared generic name.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Are 200 mg/5 mL and a 200 mg capsule the same thing?
They are not the same product-identity field. The first states an amount in each 5 mL of liquid, while the second states an amount in each capsule. Whether either can be used, measured or substituted requires the exact prescription and current label to be reviewed by a pharmacist or prescriber.
Can ZOVIRAX and VALTREX be exchanged by milligrams?
No. They are different medicines and can differ in form, label, metabolism and individual context. Do not self-switch, combine or alternate from a related antiviral use, shared household member or numbers.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.